SWTX - SpringWorks Therapeutics, Inc.

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
+0.31 (+1.13%)
收市:04:00PM EDT
27.69 0.00 (0.00%)
收市後: 04:21PM EDT
買盤0.00 x 900
賣出價0.00 x 900
今日波幅26.54 - 27.83
52 週波幅19.25 - 39.78
Beta 值 (5 年,每月)0.58
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-4.77
業績公佈日2023年8月02日 - 2023年8月07日
遠期股息及收益率無 (無)
1 年預測目標價55.80
  • Benzinga

    HC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging

    Ayala Pharmaceuticals Inc (NASDAQ: Ayala) reported data from Part A of its Phase 2 (RINGSIDE) trial evaluating AL102 in patients with desmoid tumors on Tuesday. At 16 weeks, one of 13 patients treated with AL102 demonstrated an unconfirmed partial response, which HC Wainwright believes signals encouraging initial activity. HC Wainwright reiterated the Buy rating on the stock with a price target of $18. The analyst says that Ayala's initial data is encouraging in the context of the clinical devel

  • Benzinga

    SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch

    HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. As per a survey of U.S. oncologists treating patients with desmoid tumors, roughly 80% and 87% of medical oncologists believe that nirogacestat compares favorably to Bayer AG's (OTC: BAYRY) Nexavar (sorafenib) and that they are willing to switch current patients to nirogacestat, respectively. The analysts for